Results 81 to 90 of about 14,294,829 (187)

AIDS and Non AIDS-Related Malignant Lymphoma in Tanzania. [PDF]

open access: yes, 2006
Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors. In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
Ekman, Marianne   +25 more
core   +1 more source

Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2015
Nodal peripheral T-cell lymphomas are a rare group of neoplasms derived from post-thymic and activated T lymphocytes. A review of scientific articles listed in PubMed, Lilacs, and the Cochrane Library databases was performed using the term "peripheral T ...
Luis Alberto de Pádua Covas Lage   +6 more
doaj   +1 more source

Anaplastic large-cell lymphoma.

open access: yes, 2011
The concept of anaplastic large-cell lymphoma (ALCL) has changed over the years because of a stream of new information and novel understanding regarding the cell of origin, biology, genetics, and clinical features of these neoplasms. This new information
European T. Cell Lymphoma Study Group   +3 more
core   +1 more source

A Case of Angioimmunoblastic T-Cell Lymphoma

open access: yesJournal of Clinical and Diagnostic Research
Angioimmunoblastic T-cell Lymphoma (AITL) is a rare type of peripheral T-cell lymphoma characterised by an aggressive clinical course and a poor response to current therapies. There is currently no standard of care for treatment.
Kanchan Dasharthrao Devde   +4 more
doaj   +1 more source

Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report

open access: yesClinical Case Reports
Key Clinical Message Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T‐cell lymphoma.
Sigrid De Wilde, Carlos Graux
doaj   +1 more source

Delayed diagnosis of angioimmunoblast T-cell lymphoma presenting with immunoglobulin a vasculitis

open access: yesRenal Failure
Although vasculitis and renal involvement might be associated with malignancy, they are rarely associated with lymphoproliferative diseases. We observed a case of immunoglobulin A vasculitis associated with segmental and focal glomerulonephritis in a ...
Lu Xu   +4 more
doaj   +1 more source

EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS

open access: yesMediterranean Journal of Hematology and Infectious Diseases
Epstein-Barr virus (EBV) is a prevalent virus that can be detected in the vast majority of the population. Most people are asymptomatic and remain chronically infected throughout their lifetimes.
Pietro Tralongo   +2 more
doaj   +1 more source

Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma [PDF]

open access: yes, 2019
Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver mutations have been found in TET2, IDH2, DNMT3A, RHOA, FYN, PLCG1, and CD28, whereas
Kaasinen, Eevi   +6 more
core   +1 more source

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL)

open access: yesFrontiers in Oncology, 2019
Angioimmunoblastic T-cell lymphoma (AITL) is one of four major subtypes of nodal peripheral T cell lymphoma, characterized by its cell of origin, the follicular helper T-cell (TFH).
Kelsey Sokol   +7 more
doaj   +1 more source

Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.

open access: yes, 2013
Item does not contain fulltextThe prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy.
Beckers, Marielle M.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy